CA
REGN icon

CoreCap Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

CoreCap Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$197K Sell
315
-97
-24% -$66K 0.01% 868
2026
Q1 		$318K Sell
412
-383
-48% -$293K 0.01% 636
2025
Q4 		$614K Buy
795
+557
+234% +$378K 0.02% 470
2025
Q3 		$134K Buy
238
+20
+9% +$11.3K ﹤0.01% 940
2025
Q2 		$114K Sell
218
-19
-8% -$10.6K ﹤0.01% 939
2025
Q1 		$150K Sell
237
-29
-11% -$19.9K 0.01% 759
2024
Q4 		$189K Sell
266
-2,663
-91% -$2.23M 0.01% 722
2024
Q3 		$3.08M Buy
2,929
+2,616
+836% +$2.91M 0.14% 148
2024
Q2 		$329K Sell
313
-77
-20% -$74.6K 0.03% 291
2024
Q1 		$375K Sell
390
-1,274
-77% -$1.21M 0.02% 451
2023
Q4 		$1.46M Buy
1,664
+1,412
+560% +$1.16M 0.09% 202
2023
Q3 		$207K Sell
252
-30
-11% -$23.6K 0.01% 500
2023
Q2 		$203K Buy
+282
New +$217K 0.01% 533
2022
Q4 		$421K Buy
583
+212
+57% +$156K 0.03% 385
2022
Q3 		$256K Sell
371
-2,209
-86% -$1.39M 0.02% 441
2022
Q2 		$1.52M Buy
+2,580
New +$1.68M 0.12% 136
2022
Q1 		– Sell
-229
Closed -$145K – 1722
2021
Q4 		$145K Buy
+229
New +$141K 0.01% 624

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

CoreCap Advisors's REGN Position: Q2 2026 in Review

CoreCap Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 24% in Q2 2026, selling an estimated $66K and leaving 315 shares worth $197K. The position accounts for 0.01% of the portfolio, ranked #868.

CoreCap Advisors first reported a position in REGN in Q4 2021 and has held it in 17 quarters since. The position peaked at $3.08M in Q3 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • CoreCap Advisors held 315 shares of Regeneron Pharmaceuticals worth $197K as of Q2 2026.
  • CoreCap Advisors sold 97 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $66K.
  • Regeneron Pharmaceuticals made up 0.01% of CoreCap Advisors's portfolio in Q2 2026, its #868 holding.
  • CoreCap Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2021 and has held it in 17 quarters since.
  • CoreCap Advisors's Regeneron Pharmaceuticals position peaked at $3.08M in Q3 2024.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.